NAFLD and NASH in Europe and Canada
NAFLD: Spectrum of Disease and Clinical Outcomes
The Changing Face of Liver Disease in Europe
NAFLD and Cardiometabolic Complications
Prevalence of NAFLD in Europe
Why Are NAFLD and NASH Under-Recorded?
Roles of Diabetes and Obesity in NAFLD
Prevalence of NAFLD in Canada
NAFLD and NASH in Australia
Australia's NAFLD Problem
A Snapshot of Obesity in Australia
Increasing Incidence of NASH as an Indication for LT
Natural History of NAFLD: A Multinational Cohort Study
Natural History of NAFLD: A Multinational Cohort Study Findings
Implications for Australia
NAFLD and NASH: The Global Epidemic
Obesity: At the Root of the Problem
NAFLD: A Spectrum of Disease
NAFLD and NASH: A Global Epidemic
Multiple Clinical Outcomes of NAFLD and NASH
Evidence for Progression of NASH
Forecast for Progression of NAFLD in 2015 to 2030
Forecast for Progression of NAFLD in 2015 to 2030 (cont)
NAFLD Is Associated With Multiple Conditions
Improvement in Fibrosis Improves Quality of Life
NASH Associated With High Lifetime Economic Burden
Strategies to Decrease NASH Prevalence It Begins With Identifying Patients at Risk
Off-Label Pharmacologic Treatments
Targets in the Treatment Pipeline
Drugs in Phase 2 and Phase 3 Trials for NASH
Drugs in Phase 3 Trials for NASH
REGENERATE: Positive Results of OCA Treatment for NASH
Summary: NASH
Abbreviations
Abbreviations (cont)